Vickor Medical Completes Series C Financing of Hundreds of Millions RMB and Files IPO Prospectus
Vickor
Structural Heart Disease Minimally Invasive Intervention Product Developer
Medical Device Media Reporting Pioneer
Share Professional Medical Device Knowledge
Recently, Wuhan Vickor Medical Technology Co., Ltd. ("Vickor") has successfully completed its Series C financing round, raising several hundred million RMB., fully led by Bohua Capital, a well-known investment institution in Liangxi District, Wuxi City. This round of financing will provide strong financial support for Vickor in product development, market expansion, and international strategic layout.
Since its establishment in July 2018, Vickor has consistently focused on addressing significant clinical needs within the cardiovascular field, particularly in the area of minimally invasive interventions for heart failure and structural heart disease. With core competencies in research and development, technical services, manufacturing, and sales, the company is committed to building an innovative medical device platform that provides comprehensive cardiovascular solutions throughout the patient care cycle, offering advanced products and treatment options to patients and doctors worldwide.
The medical device market in the cardiovascular field, both in China and globally, is in a phase of rapid development. With an expanding market size, technological innovation and market expansion are the main trends, presenting Vickor with tremendous growth opportunities. Against this backdrop, Vickor has successfully launched multiple innovative products thanks to its exceptional R&D capabilities and market insight, earning widespread recognition from the industry. This round of financing will further accelerate the development of new product lines, deepen market presence, and promote internationalization efforts, aiming to secure a position in the global market and contribute to improving the current state of cardiovascular disease treatment worldwide.
Currently, Vickor's product line covers multiple cardiovascular treatment areas, including atrial shunt devices and various active devices for heart failure prevention and treatment, patent foramen ovale closure devices for cardiogenic stroke prevention, transcatheter aortic valve replacement systems for treating valvular diseases, as well as related surgical accessory consumables.
It is worth mentioning that the PFO occluder and multiple配套耗材have been successfully commercialized.
Atrial Shunt Device Receives NMPA's "Special Review Procedure for Innovative Medical Devices" Certification and FDA's "Breakthrough Device" Designation.
And independently developed a transcatheter aortic valve replacement system with world-class advanced technology, simultaneously meeting the dual indications of stenosis and regurgitation. It does not require general anesthesia or pacemaker assistance, adopts a minimally invasive interventional approach, and can complete the surgery in just 40 minutes.
The Bohua Capital investment team stated: "Vickor's innovation capabilities and market performance in the cardiovascular medical device field are impressive. We believe that through close cooperation and joint efforts, we will surely achieve more brilliant results in this field."
Vickor's Founder & Chairman, Shang Xiaoke, stated: "We are extremely honored to receive recognition and support from Bohua Capital. This round of financing will bring us more resources and support, enabling us to further our efforts in the cardiovascular medical device field. With even greater determination and an innovative spirit, we will continue to advance medical technology and strive to provide patients with higher quality medical services."
Vickor's Co-founder & CEO, Wang Xueli, stated: "Vickor will continue to focus on the clinical needs in the cardiovascular field, particularly minimally invasive interventional treatments for heart failure and structural heart disease. At the same time, we will also strengthen our cooperation with medical institutions, research organizations, and upstream and downstream industry players to jointly build an innovative ecosystem in the cardiovascular healthcare sector, contributing to the sustainable development of the industry."
Vickor's Co-founder & CTO, Song Chen, stated: "This round of financing not only provides us with financial security but also affirms Vickor's strategic direction. We will take this opportunity to increase R&D efforts, expand market channels, and accelerate our internationalization."
The successful completion of Wuhan Vickor Medical Technology Co., Ltd.'s Series C financing marks a further consolidation of its leading position in the cardiovascular medical device field. Looking ahead, we are full of anticipation, confident that Vickor Medical will unwaveringly take technological innovation as its core engine, continuously develop and launch more outstanding medical products, contribute to the global cardiac health cause, and lead the industry toward an even more brilliant future!
More exciting content
Welcome to follow WeChat Video Channel
2025 Global Top 100 Medical Device Companies: The Rise of China's Strength
"First Stock in the Fight Against the Epidemic" Enters the New Energy Vehicle Market
Ying Tai Medical Acquires Vickor Medical
Medical Device Upstream Giant Cuts 7,000 Jobs
1.275 Billion, BD Medical Settlement
Cochlear, proudly launches a new benchmark in China's bone conduction technology!
NHC and MIIT Announce 51 Projects: Mindray, United Imaging, Neusoft...
The First Proton Therapy Device in South China Officially Launched
Nearly 1.8 Billion: WEGO's International Layout
Battle of the Two Major Device Giants: Abbott Emerges Victorious
BusinessBusiness cooperation email: qxzj@landianyiliao.com
